Thus our in vitro studies suggest that the effect of commonly used pan-HDAC inhibitors in CTCL cells relies on downstream effects other than DOT1L misregulation. The gene discussed is DOT1L; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.